Nuvation Bio Inc.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash and cash equivalents $908k $132.4m $101.1m $42.6m $35.7m $164.1m
Accounts receivable, net of allowance for credit loss of $nil and $nil $0 $12.7m $16.1m
Inventory $0 $11.4m
Prepaid expenses and other current assets $914k $3.6m $3.8m $1.5m $7.3m $11.5m
Interest receivable on marketable securities $1.1m $3.0m $2.5m $3.7m $3.6m $3.3m
Total current assets $1.2m $772.1m $667.3m $616.4m $526.3m $571.5m
Property and equipment, net of accumulated depreciation of $1,184 and $874, respectively $688k $786k $894k $717k $586k $564k
Intangible assets, net of accumulated amortization of $1,856 and $448, respectively $0 $4.6m $11.2m
Operating lease right-of-use assets $2.9m $3.8m $3.6m $2.4m $3.9m
Marketable securities $186.0m $633.0m $559.9m $568.6m $467.0m $365.1m
Lease security deposit $421k $421k $138k $141k $145k
Other non-current assets $0 $587k $6.6m $7.6m
Current operating lease liabilities $863k $1.2m $2.0m $1.7m $1.9m
Contract liabilities, current portion $0 $11.1m $7.5m
Liability related to revenue interest financing agreement, current portion $0 $9.6m
Short-term borrowings $0 $6.3m $5.7m
Warrant liability $11.0m $850k $353k $2.1m $0
Contract liabilities, net of current portion $0 $15.6m $11.3m
Non-current operating lease liabilities $2.2m $3.1m $2.0m $969k $2.5m
Non-current liability related to revenue interest financing agreement, net of deferred financing costs of $4,241 and $0, respectively $0 $145.8m
Long-term borrowings, net of deferred financing costs of $3,042 and $0, respectively $0 $47.2m
Total assets $145.0m $776.2m $672.1m $621.5m $540.6m $594.8m
Total liabilities and stockholders' equity $145.0m $776.2m $672.1m $621.5m $540.6m $594.8m
Accounts payable $2.2m $3.9m $2.1m $2.2m $6.3m $9.5m
Accrued expenses $4.4m $12.1m $9.8m $9.8m $32.8m $45.2m
Total current liabilities $6.6m $16.9m $13.2m $14.0m $58.2m $82.2m
Total liabilities $2.8m $30.2m $17.1m $16.4m $76.8m $289.1m
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of December 31, 2025 and December 31, 2024, 346,503,675 (Class A 345,503,675, Class B 1,000,000) and 337,837,872 (Class A 336,837,872, Class B 1,000,000) shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively 114 910.0m 927.6m 947.7m 1.4b 1.4b
Accumulated deficit ($3.1m) ($162.8m) ($267.0m) ($342.8m) ($910.7m) ($1.1b)
Accumulated other comprehensive income $1.6m ($1.2m) ($5.5m) $181k $573k ($187k)
Total stockholders' equity $5.0m $746.0m $655.1m $605.1m $463.8m $305.7m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.